

Candidiasis Therapeutics Market Size, Share, Revenue, Trends And Drivers For 2024-2033

The Business Research Company's Candidiasis Therapeutics Global Market Report 2024 – Market Size, Trends, And Forecast 2024-2033

LONDON, GREATER LONDON, UK, June 17, 2024 /EINPresswire.com/ -- The global candidiasis therapeutics market is on a steady growth trajectory, driven by factors such as the increased



incidence of candidiasis, antibiotic use and resistance, and a shift in fungal resistance patterns. The market, valued at \$3.06 billion in 2023, is projected to reach \$3.19 billion in 2024, reflecting a compound annual growth rate (CAGR) of 4.4%.



The candidiasis therapeutics market size is expected to see steady growth in the next few years. It will grow to \$3.66 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%."

The Business Research
Company

Rising Demand for Candidiasis Therapeutics
Candidiasis, a fungal infection caused by the overgrowth of
Candida species, is a growing concern globally. Factors
such as increased urbanization, environmental concerns,
and public awareness are contributing to the rising
demand for candidiasis therapeutics. Additionally, hospitalacquired infections and the use of antibiotics, which can
disrupt the body's natural microbiota and lead to fungal
overgrowth, are driving the need for effective treatment
options.

Explore the Global Candidiasis Therapeutics Market with a

Detailed Sample Report:

https://www.thebusinessresearchcompany.com/sample_request?id=13182&type=smp

Key Players and Market Trends

Major companies in the candidiasis therapeutics market, such as Pfizer Inc., Biocon Limited, and F. Hoffmann-La Roche Ltd., are focusing on developing innovative products to enhance treatment outcomes. For example, Scynexis Inc.'s BREXAFEMME (ibrexafungerp tablets) is an oral medication designed to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in

adult women. The drug works by blocking the growth of Candida albicans, the fungus that causes VVC, and has been approved by the US Food and Drug Administration (FDA) for this purpose.

Segments of the Candidiasis Therapeutics Market

The candidiasis therapeutics market covered in this report is segmented -

- 1) By Treatment Type: Medication, Surgery, Other Treatments
- 2) By Anatomy Type: Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis
- 3) By Mode of Administration: Injectable, Oral, Other Mode of Administrations
- 4) By Patient Population: Adults, Pediatrics
- 5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Geographical Insights: North America Leading the Market

North America dominated the candidiasis therapeutics market in 2023, with Asia-Pacific expected to be the fastest-growing region in the forecast period. The comprehensive report provides detailed insights into regional dynamics, market trends, and growth opportunities.

Access the Complete Report for In-depth Analysis:

https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report

Candidiasis Therapeutics Global Market Report 2024 from TBRC covers the following information:

- •Market size date for the forecast period: Historical and Future
- •Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- •Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Candidiasis Therapeutics Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on candidiasis therapeutics market size, candidiasis therapeutics market drivers and trends, candidiasis therapeutics market major players, competitors' revenues, market positioning, and market growth across geographies. The candidiasis therapeutics market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company: Digital Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report

Non-Therapeutic Biomolecules Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/non-therapeutic-biomolecules-global-market-report

Leukemia Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

About The Business Research Company

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708 Asia: +91 8897263534 Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24 florV8cR5DxlCpgmvFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/720611664

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.